Adicet Bio Reports Positive Clinical Update from ADI-001 Phase 1 Trial in Relapsed/Refractory…
Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor…